GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Pretax Margin %

Chemomab Therapeutics (STU:2QV0) Pretax Margin % : % (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Chemomab Therapeutics's Pre-Tax Income for the three months ended in Sep. 2024 was €-3.14 Mil. Chemomab Therapeutics's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, Chemomab Therapeutics's pretax margin for the quarter that ended in Sep. 2024 was %.

The historical rank and industry rank for Chemomab Therapeutics's Pretax Margin % or its related term are showing as below:


STU:2QV0's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -148.6
* Ranked among companies with meaningful Pretax Margin % only.

Chemomab Therapeutics Pretax Margin % Historical Data

The historical data trend for Chemomab Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics Pretax Margin % Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Pretax Margin %
- - - -

Chemomab Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chemomab Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Chemomab Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemomab Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Pretax Margin % falls into.



Chemomab Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Chemomab Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-22.211/0
= %

Chemomab Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-3.138/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chemomab Therapeutics  (STU:2QV0) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Chemomab Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chemomab Therapeutics Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Headlines

No Headlines